"Duloxetine Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.
| Descriptor ID |
D000068736
|
| MeSH Number(s) |
D02.886.778.260 D03.383.903.260
|
| Concept/Terms |
Duloxetine- Duloxetine
- N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide
- N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine
|
Below are MeSH descriptors whose meaning is more general than "Duloxetine Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Duloxetine Hydrochloride".
This graph shows the total number of publications written about "Duloxetine Hydrochloride" by people in this website by year, and whether "Duloxetine Hydrochloride" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 3 | 3 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 4 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 6 | 8 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
Below are the most recent publications written about "Duloxetine Hydrochloride" by people in Profiles.
-
An Interventional Response Phenotyping Study in Chronic Low Back Pain: Protocol for a Mechanistic Randomized Controlled Trial. Pain Med. 2023 08 04; 24(Suppl 1):S126-S138.
-
Duloxetine prevents bortezomib and paclitaxel large-fiber chemotherapy-induced peripheral neuropathy (LF-CIPN) in sprague dawley rats. Mol Pain. 2023 Jan-Dec; 19:17448069231185694.
-
Safe and Efficacious Use of Duloxetine in a Patient With Congenital Prolonged QT Syndrome: A Case Report. J Clin Psychopharmacol. 2022 Nov-Dec 01; 42(6):602-604.
-
Hippocampal BMP signaling as a common pathway for antidepressant action. Cell Mol Life Sci. 2021 Dec 22; 79(1):31.
-
Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy. J Neurosci. 2022 01 19; 42(3):405-415.
-
Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice. Drug Metab Dispos. 2022 02; 50(2):128-139.
-
Impact of duloxetine on male fertility: A randomised controlled clinical trial. Andrologia. 2021 Nov; 53(10):e14207.
-
Identification and functional validation of FDA-approved positive and negative modulators of the mitochondrial calcium uniporter. Cell Rep. 2021 06 22; 35(12):109275.
-
Diet and companionship modulate pain via a serotonergic mechanism. Sci Rep. 2021 02 01; 11(1):2330.
-
Gray matter reorganization underpinnings of antidepressant treatment of persistent depressive disorder. Eur Neuropsychopharmacol. 2021 02; 43:129-138.